A randomized, double‐blind, phase II study of oral histone deacetylase inhibitor resminostat plus S‐1 versus placebo plus S‐1 in biliary tract cancers previously treated with gemcitabine plus platinum‐based chemotherapy
暂无分享,去创建一个
J. Furuse | M. Ikeda | D. Sakai | N. Mizuno | Y. Nakai | M. Muto | M. Ueno | T. Moriwaki | Y. Komatsu | A. Tsuji | C. Morizane | H. Ishii | T. Kajiwara | A. Katanuma | A. Fukutomi | M. Tsuda | M. Ozaka | Y. Negoro | S. Shimizu | N. Nemoto | M. Furukawa | Shingo Kobayashi | Keigo Makino | S. Kobayashi
[1] H. Katayama,et al. Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: The FUGA-BT (JCOG1113) Randomized Phase III Clinical Trial. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] A. Maraveyas,et al. ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) che , 2019, Journal of Clinical Oncology.
[3] E. Vasile,et al. Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations. , 2019, European journal of cancer.
[4] H. Ueno,et al. Phase I study of resminostat, an HDAC inhibitor, combined with S-1 in patients with pre-treated biliary tract or pancreatic cancer , 2018, Investigational new drugs.
[5] H. Eguchi,et al. Randomized phase III study of gemcitabine, cisplatin plus S-1 (GCS) versus gemcitabine, cisplatin (GC) for advanced biliary tract cancer (KHBO1401-MITSUBA). , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] B. Quesnel,et al. Targeting MYC in multiple myeloma , 2017, Leukemia.
[7] Bin Tean Teh,et al. Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma. , 2017, Cancer discovery.
[8] H. Chang,et al. Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740 patients , 2017, Cancer Chemotherapy and Pharmacology.
[9] K. Boberg,et al. Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA) , 2016, Nature Reviews Gastroenterology &Hepatology.
[10] T. Takada,et al. Biliary tract cancer registry in Japan from 2008 to 2013 , 2016, Journal of hepato-biliary-pancreatic sciences.
[11] T. Tamura,et al. A phase I study of resminostat in Japanese patients with advanced solid tumors , 2015, Cancer Chemotherapy and Pharmacology.
[12] T. Utsunomiya,et al. Role of histone deacetylase expression in intrahepatic cholangiocarcinoma. , 2012, Surgery.
[13] N. Sasahira,et al. Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine , 2012, Investigational New Drugs.
[14] D. Cunningham,et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. , 2010, The New England journal of medicine.
[15] Y. Gong,et al. Significance of DNA methyltransferase-1 and histone deacetylase-1 in pancreatic cancer. , 2009, Oncology reports.
[16] Martin J Blaser,et al. Infection, cancer and prevention: report of the 19th International Symposium of the Foundation for Promotion of Cancer Research. , 2006, Japanese journal of clinical oncology.
[17] Y. Bang,et al. Histone Deacetylase Inhibitors for Cancer Therapy , 2006, Epigenetics.
[18] M. Shimizu,et al. Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer , 2004, British Journal of Cancer.
[19] Edward Chu,et al. Thymidylate synthase inhibitors as anticancer agents: from bench to bedside , 2003, Cancer Chemotherapy and Pharmacology.
[20] G. Peters,et al. Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. , 2002, Biochimica et biophysica acta.
[21] Peter A. Jones,et al. The fundamental role of epigenetic events in cancer , 2002, Nature Reviews Genetics.
[22] G. Aherne,et al. Comparison of thymidylate synthase (TS) protein up-regulation after exposure to TS inhibitors in normal and tumor cell lines and tissues. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.